NetworkNewsBreaks – Odyssey Health Inc. (ODYY) R
Post# of 85
(Total Views: 212)
Posted On: 09/13/2022 3:47:03 PM
NetworkNewsBreaks – Odyssey Health Inc. (ODYY) Reports Successful Safety Outcomes for Most Recent Phase of Concussion Drug Trial
Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, has completed the safety measures for the second cohort of its phase I multiday ascending dosing (“MAD”) clinical trial. According to the announcement, the trial is designed to evaluate the company’s novel drug to treat concussion: PRV-002. During the trial, healthy human subjects received the drug in order to determine its safety; for all cohorts of the trial, PRV-002 was found to be safe and was well tolerated. The company stated that during phase 1 of the MAD trial, 16 trial participants received PRV-002, with cohort 1, which consists of eight individuals, receiving a low dose of the drug, and cohort 2, which consists of eight additional individuals, receiving a higher dose of the drug. The company is now moving forward on plans for phase II of the trial, and is choosing clinical sites and preparing an investigator’s brochure. “At double the dose of the previous cohort, we saw no serious adverse events,” said Odyssey Health CEO Michael Redmond in the press release. “As we come close to completing the phase I trial, I am very pleased with the safety profile of our concussion pharmaceutical treatment, PRV-002. I’m equally pleased that the intranasal drug/device combination has functioned nicely and has been easy to operate in the clinical setting.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, has completed the safety measures for the second cohort of its phase I multiday ascending dosing (“MAD”) clinical trial. According to the announcement, the trial is designed to evaluate the company’s novel drug to treat concussion: PRV-002. During the trial, healthy human subjects received the drug in order to determine its safety; for all cohorts of the trial, PRV-002 was found to be safe and was well tolerated. The company stated that during phase 1 of the MAD trial, 16 trial participants received PRV-002, with cohort 1, which consists of eight individuals, receiving a low dose of the drug, and cohort 2, which consists of eight additional individuals, receiving a higher dose of the drug. The company is now moving forward on plans for phase II of the trial, and is choosing clinical sites and preparing an investigator’s brochure. “At double the dose of the previous cohort, we saw no serious adverse events,” said Odyssey Health CEO Michael Redmond in the press release. “As we come close to completing the phase I trial, I am very pleased with the safety profile of our concussion pharmaceutical treatment, PRV-002. I’m equally pleased that the intranasal drug/device combination has functioned nicely and has been easy to operate in the clinical setting.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)